Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects.

Saez-Llorens X, Violari A, Ndiweni D, Yogev R, Cashat M, Wiznia A, Chittick G, Harris J, Hinkle J, Blum MR, Adda N, Rousseau F; FTC-203 Study Team.

Pediatrics. 2008 Apr;121(4):e827-35. doi: 10.1542/peds.2006-3078. Epub 2008 Mar 10.

PMID:
18332076
2.
3.

Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.

Cahn P.

Expert Opin Investig Drugs. 2004 Jan;13(1):55-68. Review.

PMID:
14680453
4.

Initiation of antiretroviral therapy: implications of recent findings.

Saag MS.

Top HIV Med. 2004 Jul-Aug;12(3):83-8. Review.

5.

Emtricitabine: a novel nucleoside reverse transcriptase inhibitor.

Molina JM, Cox SL.

Drugs Today (Barc). 2005 Apr;41(4):241-52. Review.

PMID:
16034488
6.

Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.

Moreno S, Hernández B, Dronda F.

Drugs. 2007;67(10):1441-62. Review.

PMID:
17600392
7.

Emtricitabine: an antiretroviral agent for HIV infection.

Bang LM, Scott LJ.

Drugs. 2003;63(22):2413-24; discussion 2425-6. Review.

PMID:
14609348
8.

Integrase inhibitors: a novel class of antiretroviral agents.

Schafer JJ, Squires KE.

Ann Pharmacother. 2010 Jan;44(1):145-56. doi: 10.1345/aph.1M309. Epub 2009 Dec 29. Review.

PMID:
20040702
9.

Pharmacologic perspectives for once-daily antiretroviral therapy.

Anderson PL.

Ann Pharmacother. 2004 Nov;38(11):1924-34. Epub 2004 Oct 12. Review.

PMID:
15479772
10.

Emtricitabine: a review of its use in the management of HIV infection.

Frampton JE, Perry CM.

Drugs. 2005;65(10):1427-48. Review.

PMID:
15977972
11.

Emtricitabine/tenofovir disoproxil fumarate.

Dando TM, Wagstaff AJ.

Drugs. 2004;64(18):2075-82; discussion 2083-4. Review.

PMID:
15341498
12.

Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor.

Modrzejewski KA, Herman RA.

Ann Pharmacother. 2004 Jun;38(6):1006-14. Epub 2004 Apr 30. Review.

PMID:
15121999
13.
14.

The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.

Chetchotisakd P.

Expert Rev Anti Infect Ther. 2009 Sep;7(7):801-5. doi: 10.1586/eri.09.66. Review.

PMID:
19735222
15.

Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.

Wainberg MA, Cahn P, Bethell RC, Sawyer J, Cox S.

Antivir Chem Chemother. 2007;18(2):61-70. Review.

PMID:
17542150
16.

Emtricitabine (FTC) for the treatment of HIV infection.

Nelson M, Schiavone M.

Int J Clin Pract. 2004 May;58(5):504-10. Review.

PMID:
15206508
17.

Impact of once- and twice-daily dosing regimens on adherence and overall safety.

Hawkins T.

AIDS Read. 2004 Jun;14(6):320-2, 324, 329-31, 334-6. Review.

PMID:
15243968
18.

Recommendations in pediatric antiretroviral therapy.

Ikeda T, Ch'ng TW, Oleske JM.

Expert Opin Pharmacother. 2007 Feb;8(2):155-66. Review.

PMID:
17257086
19.

Antiretroviral drugs in pediatrics.

Rongkavilit C, Asmar BI.

Indian J Pediatr. 2001 Jul;68(7):641-7. Review.

PMID:
11519288
20.

Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.

Saag MS.

Clin Infect Dis. 2006 Jan 1;42(1):126-31. Epub 2005 Nov 23. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk